The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins (Q38187004)

30 August 2017

The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins (English)

1 reference

30 August 2017

1 reference

1 reference

2

Ralph A DeFronzo

1 reference

30 August 2017

Stanley Schwartz

1

1 reference

30 August 2017

1 March 2014

1 reference

30 August 2017

Current diabetes report

1 reference

30 August 2017

14

1 reference

30 August 2017

3

1 reference

30 August 2017

466

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-013-0466-9

30 August 2017

0 references

cites work

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Management of diabetes and hyperglycemia in hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intensive insulin therapy in the medical ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intensive insulin therapy and pentastarch resuscitation in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Evidence-based medicine in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Benefits and risks of tight glucose control in critically ill adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Hypoglycemia and outcome in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Laboratory risk factors for hospital mortality in acutely admitted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Hypoglycemia, diabetes, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Glucose control in the ICU--how tight is too tight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Incretins in the ICU: is insulin on its way out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0466-9

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

21 January 2018

1 reference

12 December 2020

Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project

1 reference

12 December 2020

Counterregulatory response to insulin-induced hypoglycemia in trained and nontrained humans

1 reference

12 December 2020

Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome?

1 reference

12 December 2020

Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)

1 reference

12 December 2020

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

1 reference

12 December 2020

Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

10.1007/S11892-013-0466-9

Identifiers

DOI

1 reference

PubMed ID

24515252

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24515252